Agenus Inc. (AGEN)

NASDAQ: AGEN · IEX Real-Time Price · USD
0.783
+0.006 (0.72%)
At close: Dec 1, 2023, 4:00 PM
0.791
+0.008 (1.00%)
Pre-market: Dec 4, 2023, 7:09 AM EST
0.72%
Market Cap 298.60M
Revenue (ttm) 100.90M
Net Income (ttm) -270.78M
Shares Out 381.50M
EPS (ttm) -0.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,594,758
Open 0.785
Previous Close 0.777
Day's Range 0.740 - 0.800
52-Week Range 0.610 - 3.013
Beta 1.42
Analysts Strong Buy
Price Target 8.12 (+937.44%)
Earnings Date Nov 7, 2023

About AGEN

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-C... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 4, 2000
Employees 533
Stock Exchange NASDAQ
Ticker Symbol AGEN
Full Company Profile

Financial Performance

In 2022, Agenus's revenue was $98.02 million, a decrease of -66.85% compared to the previous year's $295.67 million. Losses were -$220.29 million, 812.6% more than in 2021.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for AGEN stock is "Strong Buy." The 12-month stock price forecast is $8.12, which is an increase of 937.44% from the latest price.

Price Target
$8.12
(937.44% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Agenus Reports Third Quarter 2023 Results

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for the th...

27 days ago - Business Wire

Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third...

5 weeks ago - Business Wire

Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat cancers, today announced first-time and updated data from its ongoing botensil...

6 weeks ago - Business Wire

ESMO 2023: Agenus' Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced expanded data from the company's phase 1b stud...

6 weeks ago - Business Wire

Agenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers today announced completion of the planned patient enrollment i...

7 weeks ago - Business Wire

Agenus To Host BOT/BAL Program Update at ESMO 2023

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Company will host a corporate event ...

2 months ago - Business Wire

Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of...

3 months ago - Business Wire

Agenus to Participate in September Investor Conferences

LEXINGTON, Mass.LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that Dr. Garo Arme...

3 months ago - Business Wire

Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a pioneer in immuno-oncology, today announced a strategic initiative to prioritize and focus resources to accelerate the devel...

3 months ago - Business Wire

SaponiQx Announces Breakthrough in Scaling Up of STIMULON™ Cultured Plant Cell Adjuvant

LEXINGTON, Mass.--(BUSINESS WIRE)--SaponiQx, the adjuvant subsidiary of Agenus Inc. (NASDAQ: AGEN), specializing in saponin-based adjuvant discovery and manufacturing, has achieved a milestone in scal...

4 months ago - Business Wire

Agenus Reports Second Quarter 2023 Results

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results for the second quarter 202...

4 months ago - Business Wire

Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023

LEXINGTON, Mass.--(BUSINESS WIRE)--Immuno-oncology leader, Agenus Inc. (“Agenus”) (Nasdaq: AGEN), today announced a data update from the phase 1 expansion cohort of botensilimab (multifunctional CTLA-...

4 months ago - Business Wire

Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update

LEXINGTON, Mass.--(BUSINESS WIRE)--Immuno-oncology leader, Agenus (Nasdaq: AGEN), today announced the Company will release its second quarter 2023 financial results via press release before the market...

4 months ago - Business Wire

Agenus Expands Executive Leadership Team

LEXINGTON, Mass.--(BUSINESS WIRE)--Immuno-oncology leader, Agenus Inc. (“Agenus”) (Nasdaq: AGEN), today announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its execu...

4 months ago - Business Wire

ESMO GI Data: Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer

LEXINGTON, Mass.--(BUSINESS WIRE)--Immuno-oncology leader, Agenus (Nasdaq: AGEN), shared promising data today from its Phase 1b trial on the botensilimab and balstilimab combination at a late-breaking...

5 months ago - Business Wire

Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus (Nasdaq: AGEN), a leading immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, presented complete results ...

6 months ago - Business Wire

Agenus Announces Virtual Annual Shareholders Meeting

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus (NASDAQ: AGEN), a leading immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that its An...

6 months ago - Business Wire

Agenus to Participate in Jefferies Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of clinical and preclinical-stage cancer treatments, today announced that Dr. Garo Armen...

6 months ago - Business Wire

Agenus Provides Corporate Update and First Quarter 2023 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with an extensive pipeline of clinical and preclinical-stage cancer treatments, today provided a corporate upd...

7 months ago - Business Wire

Agenus Selected for Late-Breaking Oral Presentation at ESMO-GI

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus (Nasdaq: AGEN), a leading immuno-oncology company dedicated to developing innovative treatments for cancer and infectious diseases, today announced a data upd...

7 months ago - Business Wire

Agenus to Present at the American Society of Clinical Oncology 2023 Annual Meeting

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus (Nasdaq: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, today announced plans to present cl...

7 months ago - Business Wire

Agenus to Provide Corporate Update and First Quarter 2023 Financial Report

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus (Nasdaq: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, today announced the Company will re...

7 months ago - Business Wire

Agenus to Participate in May Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus (NASDAQ: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, today announced that Dr. Garo Armen...

8 months ago - Business Wire

Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, has been granted Fast Track De...

8 months ago - Business Wire

Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that its Boar...

8 months ago - Business Wire